A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population
Metrics: PDF 1222 views | HTML 1604 views | ?
Mai Kimura1,*, Yuichi Tamura1,2,3,4,5,*,**, Christophe Guignabert2,4, Makoto Takei1, Kenjiro Kosaki6, Nobuhiro Tanabe7,8, Koichiro Tatsumi7, Tsutomu Saji9, Toru Satoh10, Masaharu Kataoka1, Shigeo Kamitsuji11, Naoyuki Kamatani11, Raphaël Thuillet2,4, Ly Tu2,4, Marc Humbert2,3,4, Keiichi Fukuda1 and Motoaki Sano1,**
1Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
2Univ Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
3AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
4Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
5Department of Cardiology, International University of Health and Welfare Mita Hospital, Tokyo, Japan
6Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan
7Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
8Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University, Chiba, Japan
9Department of Pediatrics, Toho University, Medical Center, Omori Hospital, Tokyo, Japan
10Department of Cardiology, Kyorin University School of Medicine, Tokyo, Japan
11StaGen Co. Ltd., Tokyo, Japan
*These authors have contributed equally to this work
**These authors are co-corresponding authors
Yuichi Tamura, email: firstname.lastname@example.org
Keywords: pulmonary arterial hypertension, genome-wide association study, novel therapeutic target
Abbreviations: BMPR2: Bone Morphogenetic Protein Receptor Type 2; I/HPAH: idiopathic and heritable pulmonary arterial hypertension; GWAS: genome-wide association study; PAH: pulmonary arterial hypertension; PDE: phosphodiesterase
Received: January 10, 2017 Accepted: July 25, 2017 Published: August 24, 2017
Pulmonary arterial hypertension (PAH) is a lethal disease that often affects the young. Although Bone Morphogenetic Protein Receptor Type 2 gene (BMPR2) mutations are related with idiopathic and heritable PAH, the low penetrance and variable expressivity in PAH suggest the existence of other genetic and/or environmental factors. In this study, we aimed to identify novel genetic factors associated with PAH, irrespective of BMPR2 mutation.
We performed genome-wide association study (GWAS) in a Japanese population comprising 44 individuals with idiopathic and heritable PAH, and 2,993 controls.
Seven loci identified in the genome-wide study were submitted to the validation study, and a novel susceptibility locus, PDE1A|DNAJC10, was identified that maps to 2q32.1 (rs71427857, P = 7.9 × 10-9, odds ratio in the validation study = 5.18; 95% CI 1.86 – 14.42). We also found the augmentation of PDE1A protein in distal remodeled pulmonary artery walls in idiopathic PAH patients.
Given that phosphodiesterase 5 inhibitors are effective for the treatment of idiopathic and heritable PAH, our findings suggest that PDE1A could be a novel therapeutic target of PAH.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.